Valeant Pharmaceuticals International Inc
posted a quarterly net loss that it attributed in part to restructuring and impairment charges, and Canada’s biggest publicly traded drugmaker cut its full-year revenue outlook. Valeant’s U.S.-listed shares fell nearly 4 per cent in trading before the bell on Thursday.
Help employers find you! Check out all the jobs and post your resume.